In the NEJM editorial, Nissen spins what he sees as the worrisome story of these drugs.
To these NEJM authors and the NEJM itself, sadly we must say: Physicians, heal thyselves.
Cohen and Adashi, the NEJM article authors, offer thoughtful guidance through the ethical thicket of embryo donation.
FORBES: Making Babies: Selling Embryos, Despite Ethical Concerns, Addresses Genuine Needs
Today, NEJM reaffirmed its position even as it published letters from Merck and its co-authors denying wrongdoing.
Yesterday, NEJM published results that a particular coronavirus is in all likelihood the culprit behind the illness.
Not a big gain, but an interesting opportunity to watch the impact of an expected, but positive, NEJM study.
The deposition helped lead NEJM to issue an "expression of concern" regarding Merck's biggest study of Vioxx, called VIGOR.
The NEJM authors suffer the same disease that they accuse their myth-making colleagues of in their article: unscientific bias-itis.
The entire interview is publicly available on CardioExchange, a NEJM online community that fosters dialogue among physicians interested in cardiovascular disease.
FORBES: Researchers Who Ran Controversial Chelation Trial Respond to Questions
The NEJM study includes evidence suggesting that many rehospitalizations could be prevented.
Zometa is a more potent drug, says Dr. Matthew Smith , a Harvard Medical School professor who wrote and designed the NEJM study.
In a recent New England Journal of Medicine (NEJM) article, former Obama administration officials have also advocated a more indirect form of rationing.
Writing in the NEJM, Dr Roger Glass and Dr Umesh Parashar, of the US Centers for Disease Control, welcomed both studies as showing promising results.
In an interview, Jeffrey Drazen, the NEJM editor in chief, said that picking a method of analysis after seeing the data is bad scientific form.
As if on cue, the NEJM report written by I.
FORBES: Making Babies: Selling Embryos, Despite Ethical Concerns, Addresses Genuine Needs
According to a study published in tomorrow's New England Journal of Medicine (NEJM), a drug called pamidronate can prevent such bone weakening in prostate cancer patients.
Ironically, the NEJM diatribe came out around the same time as two U.S. Supreme Court rulings which touch upon two issues raised by Brownell and Koplan.
The NEJM article by Professor Rita Charon argued that health care professionals and patients are increasingly recognizing the importance of the stories they tell one another of illness.
According to a survey published this fall in NEJM (New England Journal of Medicine), doctors are about half as willing to prescribe a drug described in an industry-funded trial.
Today, that Vytorin study, called SEAS, and Peto's analysis are being published in the New England Journal (NEJM) and presented here at the annual congress of the European Society of Cardiology.
In May 2007, my colleague Kathy Wolski and I published an independent analysis of Avandia in the New England Journal of Medicine (NEJM), showing a statistically significant 43% increase in heart attack.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
It is the second time the NEJM has taken issue with a Vioxx trial--in December, it issued an expression of concern about the way heart risk was described in another big Merck study.
Last December, the NEJM editors published a strongly worded "expression of concern" arguing that Merck left out relevant data about cardiovascular problems that occurred among patients taking Vioxx in the trial, called Vigor.
One of those naysayers has now gone from being quoted in various media outlets to expressing his views in the once-venerable New England Journal of Medicine (NEJM) (hat tip to FDA Law Blog for flagging this).
Connecting the advice doctors give to the scientific evidence is the point of a new commentary on obesity appearing this week in the electronic edition of the respected New England Journal of Medicine (NEJM), Myths, Presumptions, and Facts About Obesity.
"From the day Vioxx was withdrawn from the market, the principal assertion from Merck has been that patients exposed for less than 18 months were not at risk, " says Steven Nissen, who heads cardiology at the Cleveland Clinic and has been one of Merck's biggest critics on Vioxx--including in a letter published alongside the NEJM correction.
应用推荐